Arcutis Biotherapeutics Inc [NASDAQ: ARQT] plunged by -$0.26 during the normal trading session on while it closed the day at $10.14.
Arcutis Biotherapeutics Inc stock has also loss -3.61% of its value over the past 7 days. However, ARQT stock has inclined by 22.46% in the 3 months of the year. Over the past six months meanwhile, it has lost -6.11% and gained 213.93% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for ARQT stock reached $1.19 billion, with 116.89 million shares outstanding and 101.40 million shares in the current float. Compared to the average trading volume of 2.41M shares, ARQT reached a trading volume of 4394679 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Arcutis Biotherapeutics Inc [ARQT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARQT shares is $18.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARQT stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Arcutis Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 28, 2024. While these analysts kept the previous recommendation, Mizuho raised their target price from $4 to $8. The new note on the price target was released on January 03, 2024, representing the official price target for Arcutis Biotherapeutics Inc stock. Previously, the target price had yet another drop from $57 to $4, while Mizuho kept a Neutral rating on ARQT stock. On October 13, 2023, analysts decreased their price target for ARQT shares from 32 to 6.
The Average True Range (ATR) for Arcutis Biotherapeutics Inc is set at 0.75, with the Price to Sales ratio for ARQT stock in the period of the last 12 months amounting to 8.98. The Price to Book ratio for the last quarter was 6.34, with the Price to Cash per share for the same quarter was set at 3.11.
ARQT stock trade performance evaluation
Arcutis Biotherapeutics Inc [ARQT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.61. With this latest performance, ARQT shares gained by 20.43% in over the last four-week period, additionally sinking by -6.11% over the last 6 months – not to mention a rise of 55.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARQT stock in for the last two-week period is set at 49.58, with the RSI for the last a single of trading hit 45.74, and the three-weeks RSI is set at 51.03 for Arcutis Biotherapeutics Inc [ARQT]. The present Moving Average for the last 50 days of trading for this stock 9.92, while it was recorded at 10.35 for the last single week of trading, and 8.19 for the last 200 days.
Arcutis Biotherapeutics Inc [ARQT]: An insightful look at the core fundamentals
Arcutis Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.19 and a Current Ratio set at 8.46.
Earnings per share (EPS) analysis for Arcutis Biotherapeutics Inc [ARQT] stock
With the latest financial reports released by the company, Arcutis Biotherapeutics Inc posted -0.73/share EPS, while the average EPS was predicted by analysts to be reported at -0.86/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.13. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARQT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Arcutis Biotherapeutics Inc go to 9.80%.
Arcutis Biotherapeutics Inc [ARQT]: Institutional Ownership
There are presently around $110.45%, or 112.92%% of ARQT stock, in the hands of institutional investors. The top three institutional holders of ARQT stocks are: JENNISON ASSOCIATES LLC with ownership of 11.57 million shares, which is approximately 9.3712%. SUVRETTA CAPITAL MANAGEMENT, LLC, holding 10.0 million shares of the stock with an approximate value of $$93.04 million in ARQT stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $$91.3 million in ARQT stock with ownership which is approximately 7.95%.
